Santori & Peters Inc’s AbbVie ABBV Stock Holding History

Santori & Peters Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-464	Closed	-$51K	–	56
2017 Q4	$51K	Buy	+464	New	+$43.7K	0.05%	111

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Santori & Peters Inc's ABBV Position: Q1 2018 in Review

Santori & Peters Inc sold out of AbbVie (ABBV) in Q1 2018, closing a stake of 464 shares — an estimated $51K sold.

Santori & Peters Inc first reported a position in ABBV in Q4 2017 and held it in 1 quarter. The position peaked at $51K in Q4 2017. 2,016 funds tracked by Wall St. Rank hold ABBV as of Q1 2018.

Santori & Peters Inc reported no remaining AbbVie position as of Q1 2018 after selling out during the quarter.
Santori & Peters Inc sold 464 AbbVie shares in Q1 2018, an estimated $51K.
Santori & Peters Inc first reported a position in AbbVie in Q4 2017 and held it in 1 quarter.
Santori & Peters Inc's AbbVie position peaked at $51K in Q4 2017.
2,016 funds tracked by Wall St. Rank held AbbVie as of Q1 2018.

Based on Santori & Peters Inc's 13F filing for Q1 2018, filed 16 Apr 2018.